GeneDx Holdings (GeneDx Holdings) Change In Receivables : $4.8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Change In Receivables?

GeneDx Holdings's change in receivables for the quarter that ended in Mar. 2024 was $4.2 Mil. It means GeneDx Holdings's Accounts Receivable declined by $4.2 Mil from Dec. 2023 to Mar. 2024 .

GeneDx Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $10.3 Mil. It means GeneDx Holdings's Accounts Receivable declined by $10.3 Mil from Dec. 2022 to Dec. 2023 .

GeneDx Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was $28.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. GeneDx Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 41.15.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. GeneDx Holdings's liquidation value for the three months ended in Mar. 2024 was $-47.5 Mil.

GeneDx Holdings Change In Receivables Historical Data

The historical data trend for GeneDx Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Change In Receivables Chart

GeneDx Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-4.57

-10.61

5.54

5.53

10.26

GeneDx Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial											9.72	0.45	0.55	-0.46	4.22

GeneDx Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.8 Mil.

GeneDx Holdings (NAS:WGS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

GeneDx Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	28.151	/	62.422	*	91
=	41.15

2. In Ben Graham's calculation of liquidation value, GeneDx Holdings's accounts receivable are only considered to be worth 75% of book value:

GeneDx Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	112.912	-	187.311	+	0.75 * 28.151	+	0.5 * 11.615
=	-47.5

GeneDx Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneDx Holdings (GeneDx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902

Website

https://www.genedx.com

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.

Executives

Kareem Saad	officer: Chief Business Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland	director, officer: Chief Executive Officer	458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley	officer: Chief Financial Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister	director, 10 percent owner	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White	officer: Chief People Officer	C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp	director, 10 percent owner	C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp	director, 10 percent owner	667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137